Charles S. Harmon

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Brian I. Rini, M. Dror Michaelson, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2008 · 392 citations · Full text

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

Suzanne George, Jean‐Yves Blay, Paolo G. Casali et al. · European Journal of Cancer · 2009 · 365 citations

Surgical Oncology, Sunitinib Malate, Gastrointestinal Oncology +9

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

Sandrine Faivre, Éric Raymond, Éveline Boucher et al. · The Lancet Oncology · 2009 · 288 citations

Hepatology, Medicine, Pharmacology +8

Malonyl Coenzyme A Decarboxylase Inhibition Protects the Ischemic Heart by Inhibiting Fatty Acid Oxidation and Stimulating Glucose Oxidation

Jason R.B. Dyck, Jie‐Fei Cheng, William C. Stanley et al. · Circulation Research · 2004 · 249 citations

Lipid Peroxidation, Metabolic Remodeling, Fatty Acid Oxidation +17

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

George D. Demetri, Christopher R. Garrett, Patrick Schöffski et al. · Clinical Cancer Research · 2012 · 136 citations · Full text